Halozyme Therapeutics, Inc. (HALO)

Environment story

Halozyme discloses minimal environmental data in its 10-K filing. Scope 1, Scope 2, and Scope 3 emissions are not disclosed, preventing full assessment of operational and supply-chain carbon footprint. No net-zero target date or renewable energy commitment is stated. The company operates pharmaceutical manufacturing and R&D facilities but does not publicize climate initiatives, renewable energy procurement, or decarbonization infrastructure investments. No major environmental controversies (toxic waste, water contamination, habitat litigation) are reported in the filing. The lack of disclosure results in deductions for missing Scope 3 emissions data and absent net-zero target, but absence of reported major controversies prevents additional penalties.

Social story

Halozyme does not disclose CEO-to-median-worker pay ratio, workforce turnover rates, diversity metrics (gender or underrepresented minorities in executive/technical leadership), or safety incident data in the provided 10-K excerpt. No active union-suppression activities, NLRB complaints, or major labor strikes are documented. The company acquired Antares (May 2022), Elektrofi (November 2025), and Surf Bio (December 2025), integrating new workforce populations, but integration-related labor or diversity policies are not detailed. Supply-chain ethics are mentioned only in the context of contract manufacturers (Avid, Catalent) and third-party suppliers; no audits for forced labor, cobalt/mineral tracing, or living-wage commitments are disclosed. Absence of documented labor violations and reported union activity yields a moderate score, but lack of transparency on pay equity and diversity prevents a higher rating.

Governance story

Halozyme maintains a classified board structure (three classes of directors), which limits stockholder ability to remove directors without cause under Delaware law and may inhibit takeover activity. Board independence percentage is not disclosed in the filing. The company has issued multiple convertible notes (2027, 2028, 2031, 2032) totaling $2.14 billion net debt, with conditional conversion features and make-whole provisions that increase acquisition costs and complicate capital structure but do not constitute dual-class voting rights. No disclosed lobbying expenditures targeting climate deregulation or consumer-protection rollbacks are reported. One active patent infringement lawsuit (Halozyme v. Merck Sharp & Dohme, filed April 2025) is disclosed, alleging Merck's infringement of MDASE™ technology; this represents active IP litigation but not regulatory enforcement or antitrust proceedings. Anti-takeover provisions (classified board, 50% stockholder threshold for special meetings, no cumulative voting) are formalized in charter documents. No SEC consent decrees, privacy fines, or antitrust settlements are mentioned.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Halozyme Therapeutics, Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Halozyme Therapeutics, Inc. in the app for interactive charts and portfolio building.

More in Healthcare